Critical Access Pharmacy Model
- APhA encourages the creation by Congress of a Critical Access Pharmacy designation for the Medicare program to ensure financial viability and high-quality care to beneficiaries in low access areas.
- APhA supports the implementation of a Critical Access Pharmacy designation by the Centers of Medicare and Medicaid Services (CMS) that incorporates both financial incentives and quality measures that improve business sustainability while maintaining quality of care.
- APhA supports the expansion of state and federal scholarships and student loan repayment programs to include pharmacists and technicians employed by Critical Access Pharmacies.
Pharmacist’s Role in Health Care Reform
- APhA affirms that pharmacists are the medication experts whose accessibility uniquely positions them to increase access to and improve quality of health care while decreasing overall costs.
- APhA asserts that pharmacists must be recognized as the essential and accountable patient care provider on the health care team responsible for optimizing outcomes through medication therapy management (MTM).
- APhA asserts the following:
- Medication Therapy Management Services: Definition and Program Criteria is the standard definition of MTM that must be recognized by all stakeholders.
- Medication Therapy Management in Pharmacy Practice: Core Elements of an MTM Service Model, as adopted by the profession of pharmacy, shall serve as the foundational MTM service model.
- APhA asserts that pharmacists must be included as essential patient care provider and compensated as such in every health care model, including but not limited to, the medical home and accountable care organizations.
- APhA actively promotes the outcomes-based studies, pilot programs, demonstration projects, and other activities that document and reconfirm pharmacists’ impact on patient health and well-being, process of care delivery, and overall health care costs.
Medicare and Patient Care Service
- APhA believes that Health care, including the essential component of patient care services, should be made available to as many people as possible in our society through the most economical system compatible with an acceptable standard of quality.
- APhA should support the Part B mechanism which is the voluntary supplementary medical insurance program financed equally by beneficiaries and the government.
- APhA should oppose laws, regulations, and policies that would restrict the Medicare drug benefit to specific, chronic diseases.
- APhA should support the inclusion of patient care services under Medicare or any other federal financing mechanism, providing the program is designed to help persons who need it most and is administratively efficient and economical.
Government-Financed Reimbursement
- APhA supports only those government-operated or -financed, third-party prescription programs which ensures that participating pharmacists receive individualized, equitable compensation for professional services and reimbursement for products provided under the program.
- APhA regards equitable compensation under any government-operated or -financed, third party prescription programs as requiring payments equivalent to a participating pharmacist’s prevailing charges to the self-paying public for comparable services and products, plus additional, documented, direct and indirect costs which are generated by participation in the program.
- APhA supports those government-operated or -financed, third-party prescription programs which base compensation for professional services on professional fees and reimbursement for products provided on actual cost, with the provision of a specific exception to this policy in those instances when equity in professional compensation cannot otherwise be attained.
Medicare, Medicaid, and Other Third-Party Payment Programs
- APhA advocates a professional fee system of reimbursement in Medicare and Medicaid and other third-party payment programs which would recognize variations in services provided and costs incurred by individual pharmacies.
- APhA supports maintaining close liaison with proponents of national health insurance programs to ensure that pharmacy will have an opportunity to make its views known in the development of such proposals.
Medicare Task Force: Policy Guidelines
The following guidelines supplement those adopted by APhA in 1967:
- Provide for beneficiary contribution toward program financing.
- Provide for government reimbursement of claims directly to the pharmacist.
- Compensate pharmacists by means of a professional fee commensurate with the level of professional service performed in addition to making reimbursement for the cost of the drugs.
- Establish a per-prescription, fixed amount (co-payment) which must be paid by the beneficiary when obtaining drugs.
- To assure patients of receiving safe and effective drugs, establish a list of reimbursable amounts for each drug based on a nationally available product of acceptable quality and cost.
- Include all drugs having therapeutic use, whether for chronic or acute conditions.
- Include all persons eligible for Part B Medicare coverage.
Drugs Provided Under Social Security Act: Guidelines for Pharmaceutical Service
Since it is probable or likely that APhA may have to consider and act upon some proposals in the area of drug costs before the next annual meeting, we recommend that APhA Board of Trustees be guided by whether the proposals:
- Permit pharmacists to select and dispense a quality drug product;
- Establish some mechanism to assist pharmacists in selecting quality, drug products under the cost and other criteria established;
- Permit the use of any available drug product when unique medical circumstances so require;
- Establish a reasonable remuneration base for pharmacists rendering services under the program;
- Guarantee recipients free choice of pharmacy; and
- Limit the reimbursement for pharmacists’ services to those provided by duly licensed pharmacists.